Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

HQL, Longthera and Medicilon Form Collaboration to Co-Develop Novel anti-cancer drug targeting

Page View:

Longthera Pharmaceuticals

04/18/2014, Longthera Pharmaceuticals, a pre-clinical stage biopharmaceutical company, based in Jiangsu Province, China, and HQL Pharmaceuticals, a drug discovery company utilizing its super power ChemSpace Scanner (CSS™) computational technology, based in Rehovot, Israel, announced that they have entered into a collaboration agreement for the development of anti cancer small-molecule drug candidate targeting the BCL-2 apoptotic pathway.

Under the terms of the agreement, HQL and Longthera will jointly continue the development of HQL’s anti-cancer apoptosis inducing program targeting the BCL-2 pathway.  Longthera will receive major part of commercial rights in China, while HQL retains the majority of the commercial rights outside of China. Medicilon, a leading pharmaceutical R&D outsourcing company in China, will provide discovery services for the program, including the development and testing of the drug candidate structural biology and initial pre-clinical development for both US FDA and CFDA IND filing.

Relevant newsRelevant news